Neurometrix (NASDAQ:NURO) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
Separately, HC Wainwright reissued a “buy” rating and set a $3.00 price objective (down previously from $10.00) on shares of Neurometrix in a report on Friday, October 20th.
Shares of Neurometrix (NASDAQ NURO) traded up $0.01 during mid-day trading on Tuesday, reaching $1.73. 25,622 shares of the company traded hands, compared to its average volume of 85,569. Neurometrix has a 12-month low of $1.45 and a 12-month high of $7.20. The firm has a market cap of $4.01, a P/E ratio of -0.10 and a beta of 0.33.
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.